Narcolepsy: Clinical features, co-morbidities & treatment

Indian Journal of Medical Research

Volumn 131, Issue 2, 2010, Pages 338-349

  Peacock, Jeremy ^a   Benca, Ruth M ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Cataplexy; Excessive daytime sleepiness; Hypocretin; MSLT; Narcolepsy

Indexed keywords

AMPHETAMINE; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; AZATHIOPRINE; DULOXETINE; HISTAMINE H3 RECEPTOR AGONIST; IMMUNOGLOBULIN; METHOTREXATE; METHYLPHENIDATE; MODAFINIL; OREXIN; OXYBATE SODIUM; PLACEBO; SELEGILINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; STEROID; TIPROLISANT; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE; NEUROPEPTIDE; OREXINS; SIGNAL PEPTIDE;

ANAMNESIS; ANXIETY; BEHAVIOR MODIFICATION; BLURRED VISION; BRADYCARDIA; CARDIOVASCULAR DISEASE; CATAPLEXY; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONGENITAL DISORDER; CONSTIPATION; DAYTIME SOMNOLENCE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DRUG ABUSE; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RESPONSE; EUPHORIA; GASTROINTESTINAL DISEASE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPNAGOGIC HALLUCINATION; INSOMNIA; NARCOLEPSY; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; ONSET AGE; ORTHOSTATIC HYPOTENSION; PARASOMNIA; PATIENT COMPLIANCE; POLYSOMNOGRAPHY; PREVALENCE; PROTEIN FUNCTION; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; REVIEW; RHINOPHARYNGITIS; SCHIZOPHRENIA; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP APNEA SYNDROME; SLEEP DISORDER; SLEEP WALKING; SOMNOLENCE; SUICIDAL IDEATION; TACHYCARDIA; THORAX PAIN; TRAUMATIC BRAIN INJURY; TREATMENT INDICATION; URINE INCONTINENCE; URINE RETENTION; VISUAL HALLUCINATION; VOMITING; XEROSTOMIA; COMPLICATION; DISORDERS OF EXCESSIVE SOMNOLENCE; METABOLISM; PROCEDURES; SLEEP DISORDERS; TREATMENT OUTCOME;

CATAPLEXY; COMORBIDITY; DIAGNOSIS, DIFFERENTIAL; DISORDERS OF EXCESSIVE SOMNOLENCE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NARCOLEPSY; NEUROPEPTIDES; POLYSOMNOGRAPHY; SLEEP DISORDERS; TREATMENT OUTCOME;

EID: 77649281629     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Longstreth WT, Jr., koepsell TD, Ton TG, Hendrickson AF, van Belle G. The epidemiology of narcolepsy. Sleep 2007; 30: 13-26.
2. Tashiro T, kanbayashi T, Iijima S, Hishakawa Y. An epidemiological study on prevalence of narcolepsy in Japanese. J Sleep Res 1992; (Suppl 1): 228.
3. Silber MH, Krahn LE, Olson EJ, Pankratz VS. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep 2002; 25: 197-202.
4. Wise MS, Arand DL, Auger RR, Brooks SN, Watson NF. Treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007; 30: 1712-27.
5. Mignot E, Hayduk R, Black J, Grumet FC, Guilleminault C. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997; 20: 1012-20.
6. Ohayon MM, Ferini-Strambi L, Plazzi G, Smirne S, Castronovo V. How age influences the expression of narcolepsy. J Psychosom Res 2005; 59: 399-405.
7. Dauvilliers Y, Montplaisir J, Molinari N, Carlander B, Ondze B, Besset A, et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 2001; 57: 2029-33.
8. Bourgin P, Zeitzer JM, Mignot E. CSF hypocretin-1 assessment in sleep and neurological disorders. Lancet Neurol 2008; 7: 649-62.
9. Picchioni D, Mignot EJ, Harsh JR. The month-of-birth pattern in narcolepsy is moderated by cataplexy severity and may be independent of HLA-DQB1*0602. Sleep 2004; 27: 1471-5.
10. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998; 50 (2 Suppl 1): S16-22.
11. Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002; 59: 1553-62.
12. Krahn LE, Pankratz VS, Oliver L, Boeve BF, Silber MH. Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status. Sleep 2002; 25: 733-6.
13. Thorpy M. Therapeutic advances in narcolepsy. Sleep Med 2007; 8: 427-40.
14. Hungs M, Fan J, Lin L, Lin X, Maki RA, Mignot E. Identification and functional analysis of mutations in the hypocretin (orexin) genes of narcoleptic canines. Genome Res 2001; 11: 531-9.
15. Willie JT, Chemelli RM, Sinton CM, Tokita S, Williams SC, kisanuki Y, et al. Distinct narcolepsy syndromes in Orexin Receptor-2 and Orexin null mice molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron 2003; 38: 715-30.
16. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000; 6: 991-7.
17. khatami R, Maret S, Werth E, Rétey J, Schmid D, Maly F, et al. Monozygotic twins concordant for narcolepsy-cataplexy without any detectable abnormality in the hypocretin (orexin) pathway. Lancet 2004; 363: 1199-200.
18. Hong S, Lin L, Jeong J, Shin Y, Han J, Lee J, et al. A study of the diagnostic utility of HLA typing, CSF Hypocretin- 1 measurements, and MSLT testing for the diagnosis of narcolepsy in 163 korean patients with unexplained excessive daytime sleepiness. Sleep 2006; 29: 1429-38.
19. Stores G, Montegomery P, Wiggs L. The psychosocial problems of children with narcolepsy and those with excessive daytime sleepiness of uncertain origin. Pediatrics 2006; 114: 198-204.
20. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet 2007; 369: 499-511.
21. American Academy of Sleep Medicine. International classification of sleep disorders: Diagnostic and coding manual, 2nd ed. Westchester, IL: American Academy of Sleep Medicine; 2005.
22. Nishino S. Clinical and neurobiological aspects of narcolepsy. Sleep Med 2007; 8: 373-99.
23. National Institute of Neurological Disorders and Stroke. Narcolepsy Fact Sheet. National Institute of Neurological Disorders and Stroke 2008. Available at: http://www.ninds.nih.gov/disorders/narcolepsy/detail_narcolepsy.htm, accessed on August 1, 2008.
24. Benca R. Narcolepsy and excessive daytime sleepiness: Diagnostic considerations, epidemiology, and comorbidities. J Clin Psychiatry 2007; 68 (Suppl 13): 5-8.
25. Ervik S, Abdelnoor M, Heier MS, Ramberg M, Strand G. Health-related quality of life in narcolepsy. Acta Neurol Scand 2006; 114: 198-204.
26. Plazzi G, Serra L, Ferri R. Nocturnal aspects of narcolepsy with cataplexy. Sleep Med Rev 2008; 12: 109-28.
27. Nishino S, kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev 2005; 9: 269-310.
28. Green PM, Stillman MJ. Narcolepsy. Signs, symptoms, differential diagnosis, and management. Arch Fam Med 1998; 7: 472-8.
29. kluge M, Schüssler P, Dresler M, Yassouridis A, Steiger A. Sleep onset REM periods in obsessive compulsive disorder. Psychiatry Res 2007; 152: 29-35.
30. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Arlington, VA: APA; 2000.
31. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540-5.
32. Dauvilliers Y, Gosselin A, Paquet J, Touchon J, Billiard M, Montplaisir J. Effect of age on MSLT results in patients with narcolepsy-cataplexy. Neurology 2004; 62: 46-50.
33. Singh M, Drake C, Roth T. The prevalence of multiple sleep-onset REM periods in a population-based sample. Sleep 2006; 29: 890-895.
34. Littner MR, kushida C, Wise M, Davila D, Morganthaler T, Lee-Chiong T, et al. Practice parameters for clinical use of multiple sleep latency test and the maintenance wakefulness test. Sleep 2005; 28: 113-21.
35. Black J, Brooks S, Nishino S. Conditions of primary excessive daytime sleepiness. Neurol Clin 2005; 23: 1025-44.
36. Leibowitz S, Brooks S, Black J. Excessive daytime sleepiness: considerations for the psychiatrist. Psychiat Clin N Am 2006; 29: 921-45.
37. Mignot E, Lin L, Rogers W, Honda Y, Qiu X, Lin X, et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 2001; 68: 686-99.
38. Riemann D. Insomnia and comorbid psychiatric disorders. Sleep Med 2007; 8 (Suppl 4): S15-20.
39. Nofzinger EA, Thase ME, Reynolds CF, Himmelhoch JM, Mallinger A, Houst P, et al. Hypersomnia in bipolar depression: a comparison with narcolepsy using the multiple sleep latency test. Am J Psychiat 1991; 148: 1177-81.
40. Dahmen N, kasten M, Mittag K, Müller MJ. Narcoleptic and schizophrenic hallucinations. Implications for differential diagnosis and pathophysiology. Eur J Health Econ. 2002; 3 (Suppl 2): S94-8.
41. Ha KS, Yoo HK, Lyoo IK, Jeong DU. Computerized assessment of cognitive impairment in narcoleptic patients. Acta Neurol Scand 2007; 116: 312-6.
42. Meltzer LJ, Mindell JA. Sleep and sleep disorders in children and adolescents. Psychiat Clin N Am 2006; 29: 1059-76.
43. Peterson PC, Husain AM. Pediatric narcolepsy. Brain Dev 2008; 30: 609-23.
44. Biederman J, Pliszka SR. Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents. J Pediatr 2008; 152: 394-9.
45. Macleod S, Ferrie C, Zuberi S. Symptoms of narcolepsy in children misinterpreted as epilepsy. Epileptic Disord 2005; 7: 13-7.
46. Arnulf I. Excessive daytime sleepiness in parkinsonism. Sleep Med Rev 2005; 9: 185-200.
47. Lee JH, Bliwise DL, Ansari FP, Goldstein FC, Cellar JS, Lah JJ, et al. Daytime sleepiness and functional impairment in Alzheimer disease. Am J Geriatr Psychiatry 2007; 15: 620-6.
48. Auger RR, Goodman SH, Silber MH, Krahn LE, Pankratz VS, Slocumb NL. Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: a case-control study. Sleep 2005; 28: 667-72.
49. Shire US Inc., "Prescribing Information" sheet (PDF) for Adderall XR. Available at: http://www.adderallxr.com/, accessed on August 1, 2008.
50. Cephalon "Prescribing Information" Sheet (PDF) for Provigil. Available at: https://www.provigil.com/hcp/default.aspx, accessed on August 2, 2008.
51. Scammell TE, Estabrooke IV, McCarthy MT, Chemelli RM, Yanagisawa M, Miller MS, et al. Hypothalamic arousal regions are activated during Modafinil-induced wakefulness. J Neurosci 2000; 20: 8620-8.
52. Morganthaler TI, Kapur VK, Brown TM, Swick TJ, Alessi C, Aurora RN, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin: An American Academy of Sleep Medicine Report. Sleep 2006; 29: 1415-9.
53. Dunlop BW, Crits-Christoph P, Evans DL, Hirschowitz J, Solvason HB, Rickels k, et al. Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. J Clin Psychopharmacol 2007; 27: 614-9.
54. Becker PM, Schwartz JR, Feldman NT, Hughes RJ. Effect of Modafinil on fatigue, mood, and health-related quality of life in patients with narcolepsy. Psychopharmacol 2004; 171: 133-9.
55. Ivanenko A, Tauman R, Gozal D. Modafinil in the treatment of excessive daytime sleepiness in children. Sleep Med 2003; 4: 579-82.
56. Tunnicliff G. Sites of action of gamma-hydroxybutyrate (GHB) - a neuroactive drug with abuse potential. J Toxicol 1997; 35: 581-91.
57. Jazz Pharmaceuticals. Prescribing Information Sheet (PDF) for Xyrem. Available at: http://www.xyrem.com/healthcare-professionals/prescribing-information.php, accessed on August 1, 2008
58. Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006; 29: 939-46.
59. Elliott S, Burgess V. The presence of gamma-hydroxybutyric acid (GHB) and gamma-butyrolactone (GBL) in alcoholic and non-alcoholic beverages. Forensic Sci Int 2005; 16: 289-92.
60. Wojtowicz JM, Yarema MC, Wax PM. Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma- butyrolactone: a case report and systematic review. CJEM 2008; 10: 69-75.
61. LeTourneau JL, Hagg DS, Smith SM. Baclofen and gamma- hydroxybutyrate withdrawal. Neurocrit Care 2008; 8: 430-3.
62. Izzi F, Placidi F, Marciani MG, Zannino S, Torelli F, Corte F, et al. Effective treatment of narcolepsy-cataplexy with duloxetine: A report of three cases. Sleep Med 2009; 10: 153-4.
63. Wyeth Pharmaceuticals. Prescribing Information Sheet (PDF) for Effexor XR. Available at: http://www.wyeth.com/content/showlabeling.asp?id=100, accessed on August 2, 2008.
64. Dauvilliers Y, Carlander B, Rivier F, Touchon J, Tafti M. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 2004; 56: 905-8.
65. Dauvilliers Y. Follow-up of four narcolepsy patients treated with intravenous immunoglobulins. Ann Neurol 2006; 60: 153.
66. Boehmer LN, Wu M-F, John J, Siegel JM. Treatment with immunosuppressive and anti-inflammatory agents delays onset of canine genetic narcolepsy and reduces symptom severity. Exp Neurol 2004; 188: 292-9.
67. Hecht M, Lin L, kushida CA, Umetsu DT, Taheri S, Einen M, et al. Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin- deficiency narcolepsy. Sleep 2003; 26: 809-10.
68. Lin JS, Dauvilliers Y, Arnulf I, Bastuji H, Anaclet C, Parmentier R, et al. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol Dis 2008; 30: 74-83.
69. Powell NB, Schechtman KB, Riley RW, Guilleminault C, Chieng RP, Weaver EM. Sleepy driver near-misses may predict accident risks. Sleep 2007; 30: 331-42.
70. kotterba S, Mueller N, Leidag M, Widdig W, Rasche K, Malin JP, et al. Comparison of driving simulator performance and neuropsychological testing in narcolepsy. Clin Neurol Neurosurg 2004; 106: 275-9.